Zacks analysts published research on 16 major stocks on October 14, 2026. Mastercard received a Neutral rating despite strong performance, citing competitive pricing pressure and premium valuation concerns. AstraZeneca faces patent erosion challenges but benefits from strong pipeline drugs and expects $80 billion in revenues by 2030. SanDisk received an Outperform rating, driven by AI inference demand and strong datacenter exposure. Other notable stocks analyzed include Exelon, General Mills, and Halozyme, with mixed outlooks across various sectors.

Halozyme Therapeutics is highlighted as an attractive growth stock pick with a Zacks Growth Score of A and Rank #1 (Strong Buy). The company demonstrates exceptional earnings growth of 112.1% projected for the year, significantly outpacing the industry average of 14.7%, along with strong asset utilization efficiency and positive earnings estimate revisions.

The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases.

Halozyme Therapeutics has demonstrated a strong track record of beating earnings estimates, surpassing consensus by an average of 14.59% over the last two quarters. With a positive Earnings ESP of +2.78% and a Zacks Rank #2 (Buy) rating, analysts suggest the company is well-positioned to continue this earnings beat streak in its upcoming quarterly report.

A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.

Halozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo.

A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $9,284.68 as of September 23, 2026, representing an 828.47% gain. The biopharmaceutical company's growth is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners. However, biosimilar competition for blockbuster drugs and dependence on partner revenues remain concerns.

Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.

Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.

Invesco S&P MidCap 400 Pure Growth ETF (RFG) is reviewed as a smart beta ETF offering mid-cap growth exposure with a 0.35% expense ratio. The fund has delivered 16.08% year-to-date returns and 18.85% over the past year, with 102 holdings primarily concentrated in Industrials (27.7%), Healthcare, and Information Technology sectors. It carries medium risk with a beta of 1.12, though cheaper alternatives like Vanguard Morningstar Mid-Cap Growth ETF (VOT) and iShares Russell Mid-Cap Growth ETF (IWP) are available.

Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.